10-K: International Stem Cell Corporation Reports Increased Product Sales in Annual 10-K Filing

Sentiment:

Annual Report 28 March 2025 4:00 PM

📋All filings for International Stem Cell CORP

International Stem Cell Corporation's 10-K filing reveals a 17% increase in product sales driven by biomedical market growth, alongside ongoing efforts in therapeutic development and a going concern uncertainty.

Capital raiseThe company will need to obtain significant additional capital from sources including exercise of outstanding warrants, equity and/or debt financings, license arrangements, grants and/or collaborative research arrangements to sustain our operations and develop products.Additional financing through strategic collaborations, public or private equity or debt financings or other financing sources may not be available on acceptable terms, or at all.

Worse than expectedThe company's net loss increased from $0.1 million in 2023 to $0.2 million in 2024.The company's cash decreased from $1.6 million at December 31, 2023 to $1.2 million at December 31, 2024.There is substantial doubt about the company's ability to continue as a going concern without additional financing.

Summary

International Stem Cell Corporation (ISCO) is a clinical stage biotechnology company focused on therapeutic and biomedical product development.
The company reported total product sales of $9.1 million for the year ended December 31, 2024, compared to $7.8 million in 2023.
This increase was primarily driven by a rise in media and cell product sales within the biomedical market segment.
ISCO is developing neural stem cells for the treatment of Parkinson's disease, traumatic brain injury, and stroke.
The company's most advanced project is the neural stem cell program for Parkinson's disease, with Phase I trial completed in June 2021.
ISCO's subsidiary, Lifeline Skin Care, Inc., develops and sells anti-aging skin care products.
The company's subsidiary, LCT, develops and commercializes human cell culture products.
ISCO faces challenges including operating losses, the need for additional capital, and competition in the biotechnology and pharmaceutical industries.
There is substantial doubt about the company's ability to continue as a going concern without additional financing.
The company is pursuing various financing options to fund its research and development programs and operations.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there's revenue growth, the company faces significant financial challenges and uncertainties about its future. The going concern warning and need for additional capital weigh heavily on the sentiment.

Positives

Product sales increased by 17% to $9.1 million in 2024.
The company's Phase 1 clinical trial for Parkinson's disease showed a potential dose-dependent response.
The company has a proprietary process based on parthenogenesis for the creation of a new type of stem cell.
The company has built the capacity to manufacture human cells for research use and for preclinical and clinical trials.
The company has a number of patents and licenses related to stem cell technology.

Negatives

The company has a history of operating losses and does not expect to be profitable in the near future.
There is substantial doubt about the company's ability to continue as a going concern without additional financing.
The company faces competition from fully integrated biotechnology and pharmaceutical companies.
The company is subject to extensive government regulation.
The company's products may be expensive to manufacture.
The company derived approximately 53% of its revenues from one customer during the year ended December 31, 2024.

Risks

The company's business is at an early stage of development, and it may not develop therapeutic products that can be commercialized.
The company will need additional capital to conduct its operations and develop its products, and its ability to obtain the necessary funding is uncertain.
The company has limited clinical testing and regulatory capabilities.
Patents held by other persons may result in infringement claims against the company.
Restrictive and extensive government regulation could slow or hinder the company's production of a cellular product.
The company may be unsuccessful in its efforts to comply with applicable federal, state and international laws and regulations.
The company may be unsuccessful in its efforts to comply with applicable federal, state and international laws and regulations.
The company may not be able to protect its proprietary technology.
The company depends on key personnel for its continued operations and future success.
The company may not have sufficient product liability insurance.
Economic uncertainties and unfavorable economic conditions could adversely affect the company's business.
The company's business is subject to risks arising from epidemic diseases or other public health emergencies.

Future Outlook

The company will need to obtain significant additional capital from sources including exercise of outstanding warrants, equity and/or debt financings, license arrangements, grants and/or collaborative research arrangements to sustain our operations and develop products.

Management Comments

Management continues to evaluate various financing sources and options to raise working capital to help fund our current research and development programs and operations.

Industry Context

The development of therapeutic and diagnostic agents for human disease is intensely competitive. Pharmaceutical companies currently offer a number of pharmaceutical products to treat Parkinsons disease, diabetes, liver diseases, and other diseases for which our technologies may be applicable.

Comparison to Industry Standards

Some of our primary competitors in the development of stem cell therapies are BioTime, SanBio, BlueRock Therapeutics, and ReNeuron.
Our primary competitors in the skin care market are Obagi, ZO Skin Health, Skinceuticals, SkinMedica (a subsidiary of Allergan), and Murad.
In the field of research products, our primary competitors for human cells, media and reagents are Lonza, EMD Millipore, Life Technologies (a subsidiary of Thermo Fisher Scientific), StemCell Technologies, Zen-bio, PromoCell, and Specialty Media.

Related Party Transactions

The company entered into a joint lease agreement with S Real Estate Holding, LLC, an affiliate of the company's Chief Executive Officer and Executive Vice President, Chief Scientific Officer.
The company borrowed a total of $2.9 million from Dr. Semechkin, Co-Chairman and CEO.

Stakeholder Impact

Shareholders face potential dilution from future equity offerings.
Employees' job security is tied to the company's ability to secure funding.
Customers may be affected by potential disruptions in product supply if the company faces financial difficulties.
Suppliers and creditors face increased risk of non-payment if the company's financial situation worsens.

Next Steps

The company will continue to pursue various financing options to fund its research and development programs and operations.
The company will continue to develop neural stem cells for the treatment of Parkinson's disease, traumatic brain injury, and stroke.
The company will continue to market and sell anti-aging skin care products through its subsidiary, Lifeline Skin Care, Inc.
The company will continue to develop and commercialize human cell culture products through its subsidiary, LCT.

Key Dates

Date	Description
2005	International Stem Cell Corporation was organized in Delaware in June 2005.
November 2004	Proposition 71 in California, which voters approved in November 2004, specifically allows state funds to be used for stem cell research.
May 2005	We entered into three exclusive license agreements (ACT IP, Infigen IP, and UMass IP or collectively ACTC agreements) with Astellas Pharma Inc. (Astellas) for the production of therapeutic products in the fields of diabetes, liver disease, retinal disease and the creation of research products in all fields.
October 2008	Dr. Russell Kern became a Director in October 2008.
December 2008	Dr. Andrey Semechkin has been a Director of the Company since December 2008.
January 2009	Significant ownership changes occurred, as defined by IRC Sections 382 and 383.
November 2009	Dr. Semechkin has served as our Chief Executive Officer since November 2009.
April 2010	The Company adopted the 2010 Equity Participation Plan.
March 2012	Amended and Restated Investors Rights Agreement dated March 9, 2012.
February 2013	Each of these license agreements was amended and restated, pursuant to which we continue to have rights to Astellas Pharmas human cell patent portfolio and non-exclusive rights to future developments in the area of diabetes and liver disease, as well as certain rights to patents covering Single Blastomere technology.
2013	We published in Nature Scientific Reports the basis for our patent on a new method of manufacturing neural stem cells which is used to produce the clinical-grade cells necessary for future clinical studies and commercialization.
August 2014	We announced the launch of a stroke program, evaluating the use of ISC-hpNSC transplantation for the treatment of ischemic stroke using a rodent model of the disease.
December 2014	Cyto Therapeutics was registered in the state of Victoria, Australia in December 2014.
November 2015	Significant ownership changes occurred, as defined by IRC Sections 382 and 383.
June 2016	We published the results of a 12-month pre-clinical non-human primate study that demonstrated the safety, efficacy and mechanism of action of the ISC-hpNSC.
October 2016	We announced the results of the pre-clinical rodent study, evaluating the use of ISC-hpNSC transplantation for the treatment of TBI.
2017	We began our Phase I trial of ISC-hpNSC, human parthenogenetic stem cell-derived neural stem cells for the treatment of Parkinsons disease.
February 2019	We published the results of the pre-clinical study in Theranostics, a prestigious peer-reviewed medical journal.
April 2019	We announced the completion of subject enrollment, with the 12th subject receiving a transplantation of the highest dose of cells.
June 2021	We announced successful completion of the dose escalating phase 1 clinical trial in June 2021.
October 2021	We entered into a joint lease agreement with S Real Estate Holding, LLC for the purpose of establishing a new corporate headquarters.
September 2023	The Company's Board of Directors voted to amend the 2010 Plan to increase the number of shares that may be issued under the 2010 Plan from 9,700,000 shares to an aggregate of 30,000,000 shares of common stock and increase the number of awards an employee may receive in a calendar year from 800,000 shares to 10,000,000 shares.
March 28, 2025	Date of the filing of the 10-K report.

Keywords

stem cells, Parkinson's disease, clinical trials, biotechnology, product sales, revenue, hpSCs, LCT, LSC, ISCO

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.